Clinical Trials | November 26, 2025
Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial
The trial tested six injectable doses and three oral doses over as long as 36 weeks
The trial tested six injectable doses and three oral doses over as long as 36 weeks
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Subscribe To Our Newsletter & Stay Updated
